Cited by 417Pharmacovigilance and Adverse Drug ReactionsStatistical Methods in Clinical TrialsPharmaceutical Economics and Policy

The DOI matches its Crossref record.

Why Drugs Fail - A Study on Side Effects in New Chemical Entities

Schuster, D., Laggner, C., Langer, T.·2005·Current Pharmaceutical Design

DOI 10.2174/138161205774414510

Open this paper in CoChat — free account

Abstract

Our study focuses on the reasons for market withdrawals of drugs and drug development project terminations in clinical phases I-III from 1992 to 2002. Over 90% of the market withdrawals were caused by drug toxicity. Hepatotoxicity and cardiovascular toxicity proved to be the major causes for two out of three market withdrawals in the respective time period. In clinical phases I-III 43% of drug development project terminations were due to insufficient efficacy of the investigated compound. The second important issue, which caused one third of the projects to be closed, was toxicity. ADME parameters and economic and other reasons played a minor role. The results of our study indicate that compared with previous studies on this subject, no major improvements have been achieved in the last decade. Keywords: market withdrawal, drug development termination, statistics

Integrity signals

Registry

Crossref · 10.2174/138161205774414510

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Sorted by citations

Items 301–400 of 413

Perception of Risk through Phases of Drug Research and Development: Questionnaire Survey
Cowlrick, I., Wolf, R., Hedner, T., et al. (2009) · Drug Information Journal · doi:10.1177/009286150904300510 · Cited by 3
“However, there is some strong similarity between the judgments collected from the present study population and with the actual findings of why drugs fail by Schuster and colleagues (1).”
Result
Rofecoxib-induced deleterious effects escape detection by organismal performance assays
Gaukler, S. M., Ruff, J. S., Morrison, L. C., & Potts, W. K. (2016) · Journal of Pharmaceutical Negative Results · doi:10.4103/0976-9234.177051 · Cited by 3
“[1] During human clinical trials, 73% of pharmaceuticals that passed preclinical safety assessments fail[2] and 10% of FDA approved pharmaceuticals are recalled after market release due to unforeseen toxicity.[3] In addition to human cost in pain, suffering and loss of life, pharmaceuticals that HHS Public Access Auth…”
Background
The Advent of the Golden Era of Animal Alternatives
Butzke, D., Grune, B., Kugler, J., Oelgeschläger, M., Seiler, A. E. M., Sittner, D., Liebsch, M., & Luch, A. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415894-8.00003-8 · Cited by 7
Predictive Toxicology: Latest Scientific Developments and Their Application in Safety Assessment
Armstrong, D., Li, S., Frieauff, W., Martus, H. ‐., Reilly, J., Mikhailov, D., Whitebread, S., & Urbán, L. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12367-4 · Cited by 3
Contemporary Practices in Core Safety Pharmacology Assessments
Baird, T. J., Gauvin, D. V., & Dalton, J. A. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-387815-1.00006-x · Cited by 4
Pyrrolopyrimidine: A Versatile Scaffold for Construction of Targeted Anti-cancer Agents
Adel, M., Serya, R. A. T., Lasheen, D. S., & Abouzid, K. A. M. (2018) · Journal of Advanced Pharmacy Research · doi:10.21608/aprh.2017.4832 · Cited by 3
“absorption, distribution, metabolism, excretion and toxicology (ADMET) is regarded as one of the main reasons for drug failure.(117,118) Thus in 2015, the pyrrolopyrimidine (compound 36) have been evaluated and compared with the established drug Erlotinib in cellular assays towards 25 cancer cell lines and by ADME/tox…”
Method
Prediction of Pharmacokinetics and Drug Safety in Humans
Bullock, P. L. (2010) · Wiley eBooks · doi:10.1002/9780470613191.ch3 · Cited by 3
In Vitro Safety Pharmacology Profiling: An Important Tool to Decrease Attrition
Hamon, J., & Whitebread, S. (2009) · Methods and principles in medicinal chemistry · doi:10.1002/9783527627448.ch12 · Cited by 3
Polypharmacology and Adverse Bioactivity Profiles Predict Potential Toxicity and Drug‐Related Adrs
Kaserer, T., Temml, V., & Schuster, D. (2014) · doi:10.1002/9781118783344.ch2 · Cited by 3
Self-citation
Predicting Drug‐Induced Hepatotoxicity:In Vitro,In SilicoandIn VivoApproaches
Xu, J. J., Kalgutkar, A. S. S., Will, Y., Dykens, J. A., Tengstrand, E., & Hsieh, F. (2009) · Methods and principles in medicinal chemistry · doi:10.1002/9783527627448.ch15 · Cited by 3
Pharmaceutically Active Supported Ionic Liquids
Cojocaru, A., Siriwardana, A. I., Gurău, G., et al. (2014) · doi:10.1002/9783527654789.ch19 · Cited by 3
Investigation of Transdermal Drug Delivery and In Vivo Pharmacokinetics of Choline Ketoprofen Ionic Liquid
Tang, Y., Wang, R., Bai, Q., et al. (2025) · ACS Materials Au · doi:10.1021/acsmaterialsau.5c00109 · Cited by 2
Repurposing of biologics and biopharmaceuticals
Israr, J., Alam, S., Singh, V., & Kumar, A. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.03.028 · Cited by 2
Morphological and Histopathological Liver Abnormalities Caused by Carbamazepine-Induced Injury in Female Albino Mice
Jaber, N. R., & Al-Bakri, N. A. (2024) · Journal of Biotechnology Research Center · doi:10.24126/jobrc.2024.18.1.778 · Cited by 2
“Drug-induced liver injury (DILI) is considered the 4th important cause of liver disease (2) and is challenging nowadays because of the large number of different drugs used (3).”
Background
Essential Oils from Phlomis longifolia Boiss. & C.I. Blanche. Aerial Parts (Flowers, Calyxes, Leaves): GC-MS Analyzes and Biological Properties
Hasan, M., Hwija, I., & Mossa, Y. (2024) · Natural Product Communications · doi:10.1177/1934578x241282866 · Cited by 2
“Unfortunately, the low rate of new drugs entering the pharmaceutical market, together with unanticipated negative side effects, contraindications, and interactions between synthetic drugs, fell short of aspirations for global health 3-7 .”
Polypharmacology in Old Drug Rediscovery: Drug Repurposing
Wang, Z., & Yang, B. (2022) · Springer eBooks · doi:10.1007/978-3-031-04998-9_13 · Cited by 4
Classification of blocker and non-blocker of hERG potassium ion channel using a support vector machine
Xuan, S., Hu, L., Wang, Z., et al. (2013) · Science China Chemistry · doi:10.1007/s11426-013-4946-1 · Cited by 2
Toxicity testing of natural products using the zebrafish model system
Pitchai, A., Kannan, R. R., & Freeman, J. L. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-823966-7.00019-0 · Cited by 2
Antioxidative and Hypoglycemic Effects of Delonix elata and Vachellia farnesiana Leaves Extracts on Streptozotocin-Induced Diabetic Male Rats
(2019) · Current Science International · doi:10.36632/csi/2019.8.4.6 · Cited by 2
“656 Currently, usage of common drugs for DM treatment is costly with strong side effects (Schuster et al., 2005).”
Background
Generation and Culture of Primary Mouse Hepatocyte–Hepatic Stellate Cell Spheroids
Mannaerts, I., Eysackers, N., & van Grunsven, L. A. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3207-9_11 · Cited by 2
Cardiovascular Safety in Drug Development
Ruiz-García, J., & Alegría‐Barrero, E. (2016) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248416639719 · Cited by 2
“In addition, it is known that over 90% of the market withdrawals are due to drug toxicity, which can lead to a huge expenditure of money and time.(8) For example, it was estimated that the financial and legal cost of withdrawing rofecoxib cost Merck around US$28 billion.”
Background
Ionic liquids as a green solvents for drugs or as an active pharmaceutical ingredient
Bashir, F., Muhammad, N., Khan, N. H., Rahim, A., Ahamad, P., Khan, A. S., Ullah, Z., & Samie, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819721-9.00004-2 · Cited by 2
Utilization ofIn VitroCytochrome P 450 Inhibition Data for Projecting Clinical Drug–Drug Interactions
Kenny, J. R., McGinnity, D. F., Grime, K., & Riley, R. J. (2010) · Pharmaceutical Sciences Encyclopedia · doi:10.1002/9780470571224.pse052 · Cited by 2
Stem Cell Technology for Embryotoxicity, Cardiotoxicity, and Hepatotoxicity Evaluation
Davila, J. C., Stedman, D. B., Engle, S. J., Pryor, H. I., & Vacanti, J. P. (2008) · Wiley eBooks · doi:10.1002/9780470431818.ch8 · Cited by 2
Non‐reproducible Research
Balas, E. A. (2018) · Wiley eBooks · doi:10.1002/9781119225898.ch6 · Cited by 2
Pharmacokinetics, quantum chemistry, and molecular modeling analysis of six potential drug candidates for Chagas disease: posaconazole, K777, phenarimol derivative, BZTS, isoxazole analog, and derivative of 4-arylaminonoline-3-carbonitrile
Morais, G. C. D. F., Corrêa, M., Campos, D. M. D. O., Sanami, S., Akter, S., Zaki, M. E. A., Fulco, U. L., & Oliveira, J. I. N. (2026) · Future Microbiology · doi:10.1080/17460913.2026.2633082 · Cited by 1
Insights and perspectives into the etiology of TKI-induced cardiotoxicity
Xu, V., Ahmed, B., Boleslav, B., Mager, D., Sparreboom, A., Sprowl, J. A., & Huang, K. M. (2026) · ASPET Discovery · doi:10.1016/j.aspetd.2026.100025 · Cited by 1
Semantic Segmentation of Microengineered Neural Tissues
Karimian, H. R., Pollard, K. J., Moore, M. J., & Kordjamshidi, P. (2019) · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/embc.2019.8856378 · Cited by 1
“Dose-limiting toxicity that is not discovered during drug development is estimated to be the secondleading cause of post-marketing drug withdrawal, and these late stage failures are generally associated with a lack of reliable screening methods for drug candidate toxicity [8], [10], [15].”
Background
Chapter 11. G Protein-Coupled Receptors: Conformational “Gatekeepers” of Transmembrane Signal Transduction and Diversification
Abrol, R., & Goddard, F. W. A. (2011) · Royal Society of Chemistry eBooks · doi:10.1039/9781849733434-00188 · Cited by 7
3D bioprinting of gastrointestinal cancer models: A comprehensive review on processing, properties, and therapeutic implications
Prashantha, K., Amita, K., & Muthappa, M. (2023) · Biointerphases · doi:10.1116/6.0002372 · Cited by 2
The hepatobiliary system of the non-human primate
Parker, G. A., McInnes, E. F., WRIGHT, J. A., et al. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-813088-9.00013-6 · Cited by 1
Inflammatory liver tissue formation using oxygen permeable membrane based culture platform
Shinohara, M., Lau, Q. Y., Torizal, F. G., Choi, H.-J., & Sakai, Y. (2023) · Journal of Bioscience and Bioengineering · doi:10.1016/j.jbiosc.2023.06.013 · Cited by 2
Thiourea as a Promising Scaffold for Development of Agents Toward TriTryp Diseases
de Souza, A. M. T., Abrahim-Vieira, B. D. A., Assumpção, P. W. M. C., et al. (2025) · ChemistrySelect · doi:10.1002/slct.202404210 · Cited by 1
Revolutionizing diabetes treatment: computational insights into 4-hydroxy isoleucine derivatives and advanced molecular screening for antidiabetic compounds
Kelam, L. M., Gill, M. S., & Sobhia, M. E. (2025) · Exploration of Drug Science · doi:10.37349/eds.2025.1008104 · Cited by 1
Comprehensive evaluation of potential EBOV inhibitors using advanced molecular modeling techniques: implications for anti-Ebola therapeutics and rational drug design
Morais, G. C. D. F., Sena, C. P. D. S., Silva, G. V. R., Alves, G. B., Vieira, D. S., Akash, S., Aktaruzzaman, M., Al-Dies, A.-A. M., Fulco, U. L., & Oliveira, J. I. N. (2025) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-025-00902-7 · Cited by 1
“About 30% of clinical-stage trials are believed to fail due to toxicity and pharmacokinetic challenges [15].”
Challenges and Responses
Zanders, E. D. (2011) · Springer eBooks · doi:10.1007/978-1-4419-9902-3_17 · Cited by 1
“Non-chemical” drugs: biologicals, protein therapeutics, vaccines and antisense therapeutics
Müller, M. (2010) · Springer eBooks · doi:10.1007/978-3-7091-0144-5_20 · Cited by 1
De-Risking Drug Discovery Programmes Early with ADMET
Tsaioun, K., & Steven, A. (2011) · InTech eBooks · doi:10.5772/27764 · Cited by 1
“Presently, a lack of efficacy and human toxicity are the primary reasons for failure (11).”
Background
Quantifying Gene Essentiality Based on the Context of Cellular Components
Jia, K., Zhou, Y., & Cui, Q. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2019.01342 · Cited by 1
Contemporary Practices in Core Safety Pharmacology Assessments
Baird, T. J., Gauvin, D. V., & Dalton, J. A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803620-4.00007-4
Learning Representations to Augment Statistical Analysis of Drug Effects on Nerve Tissues
Karimian, H. R., Pollard, K. J., Moore, M. J., & Kordjamshidi, P. (2020) · Studies in computational intelligence · doi:10.1007/978-3-030-53352-6_26 · Cited by 1
The GSK Bioanalytical Hub Model in Bioanalysis: Maximizing the Synergies of Co-Locating Various Platforms in Support of Regulated and Nonregulated Study end Points
Summerfield, S. G., Tang, H., Decman, V., Abberley, L., Gunn, G. R., & Yang, E. (2023) · Bioanalysis · doi:10.4155/bio-2022-0180 · Cited by 1
The Role of Ionic Liquids in the Pharmaceutical Manufacturing Processes
Wang, H., Zhou, X., Gurău, G., et al. (2012) · doi:10.1002/9780470711828.ch17 · Cited by 1
Toxicogenomics: Applications to In Vivo Toxicology
Semizarov, D., & Blomme, E. A. G. (2008) · Wiley eBooks · doi:10.1002/9780470409770.ch5 · Cited by 1
Drug‐Induced Liver Injury: Clinical and Diagnostic Aspects
Senior, J. R. (2015) · Methods and principles in medicinal chemistry · doi:10.1002/9783527673643.ch05 · Cited by 1
Cardiovascular Liabilities of Drugs: Regulatory Aspects
Arrigoni, C. (2010) · doi:10.1002/9780470660379.ch2 · Cited by 2
The impact of preclinical drug safety on R&D productivity
Hurko, O. (2006) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.1.4.369 · Cited by 1
“Safety issues also account for > 90% of withdrawals of marketed pharmaceuticals [2].”
Background
What are we looking for in new antibacterials and how do we design it?
Barrett, J. F., & Motyl, M. R. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.2.85 · Cited by 1
The Application of Preclinical Toxicogenomics for Predicting and Understanding Drug‐Induced Toxicity and Metabolism
Fielden, M. R., & Karbowski, C. M. (2012) · Wiley eBooks · doi:10.1002/9780470921920.edm078 · Cited by 1
Compound Attrition at the Preclinical Phase
Hop, C. E. C. A. (2015) · Wiley eBooks · doi:10.1002/9781118819586.ch2 · Cited by 1
Fast Chromatography with UPLC and Other Techniques
Wainhaus, S. B. (2009) · CRC Press eBooks · doi:10.1201/9781420092219-c8 · Cited by 1
Translational Modeling and Simulation for Molecularly Targeted Small Molecule Anticancer Agents: Case Studies of Multiple Tyrosine Kinase Inhibitors, Crizotinib and Lorlatinib
Yamazaki, S. (2018) · Methods and principles in medicinal chemistry · doi:10.1002/9783527801756.ch16 · Cited by 1
Hierarchical Coculture of Hepatocyte and Hepatic Non-Parenchymal Cells for Liver Fibrosis Studies in vitroPreprint
Lau, Q. Y., Torizal, F. G., Shinohara, M., & Sakai, Y. (2020) · Preprints.org · doi:10.20944/preprints202010.0409.v1
“Animal testing is still the most common preclinical assessment mode, but sometimes, there is poor prognostic value regarding both efficacy and toxicity in terms of the human physiological response [5,6].”
Background
Postmarketing Safety Evaluation: Monitoring, Assessing, and Reporting of Adverse Drug Responses
Gad, S. C. (2010) · doi:10.1002/9780470464151.ch24 · Cited by 1
Antidiabetic effect of 1-deazapurines derivatives with alpha-glucosidase Enzyme: A molecular tools approachPreprint
Hacene, F. B., Cherrak, S. A., Soufi, W., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.20.581286 · Cited by 1
DRUG RESEARCH AND DEVELOPMENT - CASE SCENARIOS, DEVELOPMENT PROCESS, RISKS AND BENEFITS
Cowlrick, I. (2011) · Gothenburg University Publications Electronic Archive (Gothenburg University) · Cited by 1
Screening virtual basado en topología molecular: una nueva metodología en el descubrimiento de agentes anticonvulsivos
Talevi, A. (2007) · doi:10.35537/10915/2353
In SilicoMethods for the Analysis of Metabolites and Drug Molecules
Khanna, V., & Ranganathan, S. (2010) · Wiley eBooks · doi:10.1002/9780470892107.ch17 · Cited by 1
Focus on the Fundamentals: Toward Better Therapeutic Index Prediction
Xu, J. J., & Yu, L. J. (2008) · Wiley eBooks · doi:10.1002/9780470431818.ch1
Regulatory Issues: Safety and Toxicology Assessment
Guzmán, A. (2014) · Methods and principles in medicinal chemistry · doi:10.1002/9783527679348.ch05
Predicting drug-induced liver injury: safer patients or safer drugs?
Xu, J. J. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511779053.006
Introduction: Drug Discovery in Difficult Times
MacCoss, M. (2012) · doi:10.1002/9781118219683.ch1
Drug Metabolism in Regulatory Guidances, Clinical Trials, and Product Labeling
Milton, M. (2010) · Wiley eBooks · doi:10.1002/9780470571224.pse126
Organs-On-Chips: Exploring The Utility Of Biosynthesised Organ Tissue To Improve Efficiency Of The Drug Development Process
Middelkamp, H. H. T., Stamatialis, D. F., & Jzerman, M. (2015) · Value in Health · doi:10.1016/j.jval.2015.09.1636
Towards Identifying Potential Liver Toxicity Genomic Biomarkers
Chang, C. (2011) · Personalized Medicine · doi:10.2217/pme.11.84
Translational Concept and Determination of Drug Absorption
Yanni, S. B. (2015) · Wiley eBooks · doi:10.1002/9781118838440.ch1
FORUM SERIES, PART IV Toxicity Testing in the 21st Century: A View from the Pharmaceutical Industry
MacDonald, J. S., & Robertson, R. T. (2009)
Humanin VitroADMET and Prediction of Human Pharmacokinetics and Toxicity Liabilities at the Discovery Stage
Tsaioun, K. (2014) · Royal Society of Chemistry eBooks · doi:10.1039/9781782620136-00110
Toxicogenomics-Based Assessment of Xenobiotic-Induced Oxidative Stress
Karbowski, C. M., Martin, M. M., & Nioi, P. (2015) · Oxidative stress in applied basic research and clinical practice · doi:10.1007/978-3-319-19096-9_25
Topología molecular aplicada a la búsqueda de nuevos fármacos para el tratamiento de la epilepsia refractaria
Ianni, M. E. D. (2015) · doi:10.35537/10915/51575
Current Status and Implications of Transporters: QSAR Analysis Method to Evaluate Drug–Drug Interactions of Human Bile Salt Export Pump (ABCB11/BSEP) and Prediction of Intrahepatic Cholestasis Risk
Ishikawa, T., Fukami, T., Nagakura, M., & Hirano, H. (2015) · Royal Society of Chemistry eBooks · doi:10.1039/9781782622376-00333
"Personalized medicine will have the same impact on the efficiency of drug development as aviation has on business, mobility of the work force and advancement of science."
Lee, V. H. L. (2010)
Translational Tools toward Better Drug Therapy in Human Populations
Yanni, S. B. (2015) · doi:10.1002/9781118838440.ch9
ADVANCES IN APPLICATIONS OF NANOTECHNOLOGY TO DRUG DELIVERY
Bellera, C. L., Enrique, A., Talevi, A., & Bruno‐Blanch, L. E. (2013) · Apple Academic Press eBooks · doi:10.1201/b16368-2
Stem Cells for Drug Screening
Kang, H. Y., & Jeung, E. (2016) · Stem cell biology and regenerative medicine · doi:10.1007/978-3-319-33270-3_2
Stem Cells
Handral, H. K., Sriram, G., & Cao, T. (2016) · doi:10.1002/9781119135449.ch3
Discoveries of Targets and Novel Agents for the Treatment of Ischemic Retinopathy and Neovascular Disease
Toutounchian, J. J. (2016) · doi:10.21007/etd.cghs.2016.0409
“Between 1992-2002, ≈33% of Phase III drug failures were attributed to an unacceptable side effect profile [259].”
Background
Recapitulating Development to Generate Kidney Organoid Cultures
Little, M. H., Takasato, M., Soo, J. Y.-C., & Forbes, T. A. (2017) · Springer eBooks · doi:10.1007/978-981-10-3768-9_11 · Cited by 1
Novel Sources of Antimicrobials
Nirmala, L., & Zyju, D. P. (2017) · Springer eBooks · doi:10.1007/978-981-10-4284-3_13 · Cited by 1
Regulatory Aspects for Drug Development
Coles, L. D., Klitgaard, H., Kuker, M., et al. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804066-9.00006-7
Pharmacophore Models for Toxicology Prediction
Schuster, D. (2018) · Computational Toxicology · doi:10.1002/9781119282594.ch5 · Cited by 1
Self-citation
Mass spectrometry methods for profiling xenobiotic distribution in biofluids and whole tissues
Swales, J. G. (2018) · Sheffield Hallam University · doi:10.7190/shu-thesis-00089
Hepatic Toxicity
Xu, J. J., & Hoffmaster, K. A. (2010) · doi:10.1002/9780470915110.ch8
DRUG-INDUCED LIVER INJURY: A PREDICTIVE MODEL, MITOCHONDRIAL TOXICITY MECHANISMS RISK, AND ANTIPSYCHOTIC MEDICATIONS RISK IN A REAL-WORLD SETTING
Rana, P. (2020) · Digital Commons - URI (University of Rhode Island) · doi:10.23860/rana-payal-2020
In Silico ADME: Rule-Based Systems
Talevi, A. (2021) · Springer eBooks · doi:10.1007/978-3-030-51519-5_148-2
OptNCMiner: A deep learning approach for the discovery of natural compounds modulating disease-specific multi-targetsPreprint
Shin, S. H., Oh, S. M., Park, J. H. Y., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1467387/v1
Postmarketing Safety Evaluation: Monitoring, Assessing, and Reporting of Adverse Drug Responses
(2010) · Pharmaceutical Sciences Encyclopedia · doi:10.1002/9780470571224.pse150
Safety Pharmacology
Baird, T. J., Dalton, J. A., & Gauvin, D. V. (2014) · CRC Press eBooks · doi:10.1201/b16632-22
In Silico ADME: Rule-Based Systems
Talevi, A. (2021) · Springer eBooks · doi:10.1007/978-3-030-51519-5_148-1 · Cited by 1
Biologics
Jilma, B., & Müller, M. (2016) · Springer eBooks · doi:10.1007/978-3-319-27347-1_19
Drug Metabolism in Regulatory Guidances, Clinical Trials, and Product Labeling
Milton, M. (2008) · Wiley eBooks · doi:10.1002/9780470439265.ch27
Front Matter
Kalgutkar, A. S. S., Dalvie, D., Obach, R. S., et al. (2012) · Methods and principles in medicinal chemistry · doi:10.1002/9783527655748.fmatter
POSTMARKETING SAFETY EVALUATION
Gad, S. C. (2016) · doi:10.1002/9781119097440.ch29
Current awareness: Pharmacoepidemiology and drug safety
(2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1176
In Silico ADME: Rule-Based Systems
Talevi, A. (2022) · Springer eBooks · doi:10.1007/978-3-030-84860-6_148
POSTMARKETING SAFETY EVALUATION: MONITORING, ASSESSING, AND REPORTING OF ADVERSE DRUG RESPONSES ( ADRs )
Gad, S. C., & Sullivan, D. W. (2022) · doi:10.1002/9781119755883.ch31
Culture methods focusing on bile canalicular formation using primary human hepatocytes in short timePreprint
Sakai, Y., Matsumura, M., Iwao, T., & Matsunaga, T. (2022) · Research Square · doi:10.21203/rs.3.rs-2384009/v1
Leveraging ADME/PK information to enable knowledge-driven decisions in drug discovery and development
Wienkers, L. C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-817134-9.00021-0
Development of a translational bioengineered microenvironment model to advance pre-clinical acute myeloid leukaemia research
Bray, L. J. (2023) · Queensland University of Technology · doi:10.5204/thesis.eprints.241518
Revolutionizing Diabetes Treatment: Computational Insights into 4- Hydroxy isoleucine Derivatives and Advanced Molecular Screening for Anti-Diabetic CompoundsPreprint
Kelam, L. M., Gill, M. S., & Sobhia, M. E. (2024) · Research Square · doi:10.21203/rs.3.rs-4575416/v1

Authors: Schuster, D., Laggner, C., & Langer, T.
Affiliations: Universität Innsbruck (AT)
ORCID: Schuster, D.
Laggner, C.
Langer, T.
Venue: Current Pharmaceutical Design
Publisher: Bentham Science Publishers Ltd.
Published: 2005-10-01
Volume: 11
Issue: 27
Pages: 3545-3559
ISSN: 1381-6128 (ISSN-L)
DOI: 10.2174/138161205774414510
OpenAlex: W2141455139
Cited by: 417
References: 0
Citations by year: 2026: 7 · 2025: 10 · 2024: 14 · 2023: 30 · 2022: 17 · 2021: 11 · 2020: 21 · 2019: 17 · 2018: 21 · 2017: 23 · 2016: 27 · 2015: 30 · 2014: 21 · 2013: 22 · 2012: 32
FWCI: 13.04
Type: journal article
Language: en
Open access: closed
Locations: Current Pharmaceutical Design (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
Keywords: drug failure, drug toxicity, hepatotoxicity, cardiotoxicity, adverse drug reactions, new chemical entities, drug efficacy
MeSH terms: Humans, Product Surveillance, Postmarketing, Drugs, Investigational, Treatment Failure, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Why Drugs Fail - A Study on Side Effects in New Chemical Entities

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cited by

Related

Metadata

Record

About these checks